Pharmaceutical composition containing ginkgo leaf extract and adrenoceptor agonist

A receptor agonist, epinephrine technology, applied in the field of treatment of respiratory system diseases, can solve the problems such as no obvious advantages in treatment effect and complex pathogenesis, so as to reduce clinical dosage, sensitize bronchial dilatation, and avoid adverse reactions. Effect

Active Publication Date: 2006-09-06
LUNAN HOPE PHARM CO LTD
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the complex pathogenesis of respiratory diseases such as asthma, chronic bronchitis and chronic obstructive pulmonary disease, many drugs cannot achieve satisfactory curative effect when used alone. In addition to the serious adverse reactions caused by the use of corticosteroids, there is no obvious advantage in the treatment of such diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Example 1 and Example 2 are animal experiments on the efficacy verification of the combined use of Ginkgo biloba extract and adrenergic receptor agonist.

[0014] Example 1

[0015] Effects of Ginkgo biloba extract combined with salmeterol or formoterol on histamine-induced guinea pig

[0016] Influence of Asthma Attack Latency

[0017] 1. Purpose of the experiment:

[0018] To verify the effect of ginkgo biloba extract combined with salmeterol on the onset latency of histamine-induced guinea pig asthma, and to find a more effective pharmaceutical composition for the treatment of respiratory diseases such as asthma, bronchitis and chronic obstructive pulmonary disease.

[0019] 2. Experimental materials

[0020] 1 Experimental animals: select young guinea pigs, weighing 150-200g.

[0021] 2 Experimental instruments: air compressor, aerosol nozzle, mercury manometer, 4L glass bell;

[0022] 3 Experimental drugs: 2% acetylcholine chloride...

Embodiment 2

[0038] Effects of Ginkgo biloba extract combined with clenbuterol or albuterol on histamine-induced guinea pig

[0039] Influence of Asthma Attack Latency

[0040] 1. Purpose of the experiment:

[0041] To verify the effect of ginkgo biloba extract combined with clenbuterol or albuterol on the latency of histamine-induced asthma in guinea pigs, and to find a more effective drug combination for the treatment of respiratory diseases such as asthma, bronchitis and chronic obstructive pulmonary disease things.

[0042] 2. Experimental materials:

[0043] Ginkgo biloba extract (lactone content > 80%), clenbuterol, salbutamol.

[0044] Yu ditto.

[0045] 3. Experimental method:

[0046] Select juvenile guinea pigs, both male and female, with a body weight of 150-200 g, put them into a glass cover of about 5 liters, and spray a volumetric mixture of 2% acetylcholine chloride and 0.1% histamine phosphate at a pressure of 400 mmHg for 15 seconds. After the...

Embodiment 3

[0062] Compound Aerosol of Ginkgo Biloba Extract and Salmeterol

[0063] Salmeterol 2.5g

[0064] Ginkgo Biloba Extract 200g

[0065] Ethanol 650g

[0066] Propylene glycol 250g

[0067] Dichlorodifluoromethane 1500g

[0068] Vitamin C 7.5g

[0069] Preparation Process:

[0070] Add the prescribed amount of salmeterol and ginkgo biloba extract into the well-stirred vitamin C, ethanol and propylene glycol, stir, heat in a warm water bath to dissolve the raw materials, filter with a sand core funnel, fill in divided doses, and seal the dose valve The system is respectively pressurized and injected with dichlorodifluoromethane to obtain the product. Theoretical filling is 1000 bottles, and the filling yield is above 85%. After 30 minutes of leak detection in a water bath at 45-50°C, there is no leakage. Each bottle contains 50 presses, and each press contains 50 μg of salmeterol and 4 mg of ginkgo biloba extract.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

This invention supplies a drug composition used to cure asthma, bronchitis, chronic obstructive pulmonary disease, and other respiratory diseases. The drug contains two active constituents: gingko-leaf extract and epinephrine receptor stimulator. In experiment we get a unexpected effect: the gingko-leaf extract engenders notable synergism effect withª‰-epinephrine receptor stimulator, and this has crucial meaning to clinical therapy of asthma, bronchitis, chronic obstructive pulmonary disease. Compound preparation types of aerosol, spray, powder aerosol, capsule, slow release capsule, soft capsule, common tablet, slow release tablet, disperse tablet, buccal tablet, droplet, and so on are not only propitious to quickly exert drug curative effect, but also are convenient to take.

Description

technical field [0001] The invention belongs to a new pharmaceutical composition, especially for the treatment of respiratory diseases such as asthma, chronic bronchitis and chronic obstructive pulmonary disease. Background technique [0002] The current understanding of the pathogenesis of asthma has changed from bronchial smooth muscle contraction to airway hyperresponsiveness and airway chronic inflammation, and the focus of asthma treatment has also changed from bronchial expansion to anti-inflammatory therapy. Inhaled corticosteroids should be the first choice for monotherapy of this disease. Inhaled corticosteroids can not only effectively improve airway function, relieve symptoms, reduce the number of recurrences, but also prevent airway reconstruction that causes irreversible airway obstruction. However, asthma cannot be completely cured in a short period of time, and many patients need to take medicine for a long time or even for life. The serious adverse reactions ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/16A61K9/12A61K9/20A61K9/48A61P11/06A61P11/00
Inventor 赵志全
Owner LUNAN HOPE PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap